SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN), a biopharmaceutical company, is focused on developing and commercializing innovative therapeutics designed to treat life-threatening diseases. The company’s strategy is to in-license late-stage clinical products, and then develop them for commercialization throughout the world. SciClone simultaneously strives to increase revenues and important cash flow to fund the expansion of its business as well as the development of a worldwide product portfolio. For further information, visit the Company’s web site at www.sciclone.com.
- 17 years ago
QualityStocks
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Prices $344.4 Million in PIPEs to Launch Digital Asset Treasury Strategy
Predictive Oncology (NASDAQ: POAI) announced the pricing of two concurrent private placement transactions totaling approximately…
-
QualityStocksNewsBreaks – Massimo Group (NASDAQ: MAMO) Unveils 2026 MVR Series With First HVAC-Equipped Electric Carts
Massimo Group (NASDAQ: MAMO) announced the launch of its 2026 MVR Series, introducing the MVR HVAC…
-
QualityStocksNewsBreaks – Fifty 1 Labs, Inc. (OTC: FITY) Signs LOI to Acquire BioSpark AI Technologies
Fifty 1 Labs (OTC: FITY) announced it has signed a Letter of Intent to acquire…